Smiths Detection and Novartis to Develop Infectious Disease Dxs Based on LATE PCR Tech

Smiths Detection Diagnostics and Novartis Diagnostics plan to develop and market highly multiplexed assays for a variety of infectious diseases, beginning with a focus on healthcare-associated infections.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.